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SCIENTIFIC EDITORIAL
The  new  ESC/EACTS  Guidelines  on  the  management
of  valvular  heart  disease
Les  nouvelles  recommandations  de  la  Société  européenne  de  cardiologie  et  de
l’Association  européenne  de  chirurgie  cardiothoracique  sur  la  prise  en  charge
des valvulopathies
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An  update  of  the  existing  European  Society  of  Cardiology  (ESC)  guidelines,  published  in
2007  [1],  was  felt  necessary  for  two  main  reasons.  Firstly,  new  evidence  has  accumulated,
particularly  on  risk  stratiﬁcation;  in  addition,  diagnostic  methods  and  therapeutic  options
have  changed  due  to  further  development  of  surgical  valve  repair  and  the  introduction  of
percutaneous  interventional  techniques,  mainly  transcatheter  aortic  valve  implantation
(TAVI).  Secondly,  the  importance  of  a  collaborative  approach  between  cardiologists  and
cardiac  surgeons  in  the  management  of  patients  with  valvular  heart  disease  (VHD)  — in
particular  when  they  are  at  increased  perioperative  risk  — has  led  to  the  production  of
a  joint  document  by  the  ESC  and  the  European  Association  for  Cardio-Thoracic  Surgery
(EACTS)  [2].  The  Task  Force  comprised  a  similar  number  of  cardiologists  and  surgeons,  and
this  strong  interaction  reﬂects  the  importance  of  close  collaboration  in  clinical  practice,
particularly  in  high-risk  patients.  These  guidelines  emphasize  the  need  for  a multidis-
ciplinary  approach  structured  in  the  ‘Heart  Team’,  which  should  include  cardiologists,
cardiac  surgeons,  imaging  specialists,  anaesthetists  and  other  specialists,  if  needed.Patient evaluation
With  regard  to  patient  evaluation,  as  was  the  case  in  the  previous  document,  the  Task
Force  highlighted  that  after  a  comprehensive  clinical  examination,  echocardiography  is
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he  key  examination  to  conﬁrm  diagnosis  and  assess  severity
nd  prognosis.  As  stated  in  the  documents  from  the  Euro-
ean  Association  of  Echocardiography,  which  are  used  as
eferences,  whatever  the  value  of  quantitative  parameters
he  evaluation  of  the  severity  of  valve  disease  should  result
rom  an  integrated  approach  [3—5]. The  physician  should
heck  consistency  between  the  different  echocardiographic
ndings  evaluating  severity,  mechanism  anatomy  of  valvular
isease  and  the  clinical  assessment.
Other  than  the  widespread  use  of  echocardiography,  the
se  of  stress  testing  is  encouraged  in  asymptomatic  patients.
he  Task  Force  acknowledges  that  exercise  echocardiogra-
hy  may  provide  additional  information  in  aortic  stenosis,
itral  regurgitation  and  mitral  stenosis;  however,  this  tech-
ique  could  be  technically  demanding  and  requires  speciﬁc
xpertise.  Magnetic  resonance  imaging  is  the  alternative
rocess  for  valve  regurgitation  and  left  ventricular  function
f  echocardiography  is  inadequate.  Now  multislice  computed
omography  plays  a  crucial  role  for  work-up  of  patients
efore  TAVI.
The  Task  Force  emphasizes  the  difﬁculty  of  the  decision-
aking  process  in  patients  with  valve  disease.  Risk  scores
uch  as  the  EuroSCORE  or  STS  scores  have  been  used  in
ractice  for  years  and  provide  relatively  good  discrimina-
ion,  but  the  calibration  is  poor  in  high-risk  patients,  with  an
verestimation  of  the  risk  [6].  Other  factors,  such  as  frailty
nd  anatomical  conditions  such  as  porcelain  aorta  signiﬁ-
antly  increase  the  risk,  but  are  not  included  in  current  risk
cores.  In  the  absence  of  a  perfect  risk  score,  the  Task  Force
learly  stated  that  such  scores  should  be  included  in,  but  not
e  substitutes  for,  the  clinical  judgement  of  the  Heart  Team.
peciﬁc valvular diseases
he  changes  in  the  speciﬁc  chapters  since  the  2007  ESC
uidelines,  with  regard  to  therapeutic  options,  are  as  fol-
ows.
In  aortic  regurgitation  where  pathology  of  the  aortic  root
s  frequent,  the  Task  Force  reassessed  the  thresholds  for
ntervention  on  the  ascending  aorta.  In  the  light  of  recent
tudies  on  the  natural  history,  it  was  felt  that  in  patients
ith  Marfan  syndrome,  surgery  is  indicated  when  the  maxi-
al  ascending  aortic  diameter  is  greater  or  equal  to  50  mm,
hile  the  threshold  for  intervention  should  be  lower  in
atients  with  risk  factors  for  progression.  In  cases  with  bicus-
id  aortic  valve,  the  new  threshold  is  50  mm  for  patients
ith  risk  factors  and  55  mm  for  all  others.  The  thresholds
re  lower  if  aortic  valve  replacement  is  combined  with  the
reatment  of  aortic  root  disease  or  if  valve  repair  is  per-
ormed.
In  aortic  stenosis,  among  the  new  treatments  reviewed
n  the  guidelines,  the  most  important  is  TAVI,  which  was
ntroduced  for  the  ﬁrst  time  in  the  valve  guidelines.  TAVI
s  recommended  only  ‘in  hospitals  with  cardiac  surgery  on-
ite’  and  with  a  Heart  Team  available  to  assess  individual
atient  risks.  The  indications  for  TAVI  are  based  on  the
esults  of  large  European  registries  and  also  importantly
n  results  of  the  randomized  PARTNER  trials  [7,8]. TAVI  is
ndicated  in  patients  with  severe  symptomatic  aortic  steno-
is  who  are  judged  by  the  Heart  Team  as  unsuitable  for
alve  replacement.  TAVI  should  be  considered  for  high-risk
t
a
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atients  with  severe  symptomatic  aortic  stenosis  based  on
he  individual  risk  proﬁle  as  assessed  by  the  Heart  Team,
ather  than  on  thresholds  of  risk  scores.  The  guidelines
mphasize  that  at  present  TAVI  should  not  be  performed  in
atients  at  low  or  intermediate  risk  for  surgery,  for  whom
o  supporting  data  are  currently  available.
In  the  newly  recognized  entity  of  paradoxical  low-ﬂow,
ow-gradient  aortic  stenosis  with  normal  ejection  fraction,
ortic  valve  replacement  should  be  considered  in  symp-
omatic  patients  with  low-ﬂow,  low-gradient  (<  40  mmHg)
ortic  stenosis  with  normal  ejection  fraction  only  after
liminating  all  potential  errors  of  measurements  and  if  com-
rehensive  evaluation  suggests  signiﬁcant  obstruction.
The  debate  on  the  indications  for  aortic  valve  replace-
ent  in  asymptomatic  patients  is  ongoing.  In  light  of  the
ecent  data,  surgery  should  be  considered  in  patients  at
ow  operative  risk,  with  normal  exercise  performance,  with
ery  severe  aortic  stenosis  or  progressive  disease.  Surgery
ay  also  be  considered  in  patients  with  markedly  elevated
atriuretic  peptide  levels,  signiﬁcant  increase  of  mean  pres-
ure  gradient  by  exercise  echocardiography  or  excessive  left
entricular  hypertrophy.
In  mitral  regurgitation, the  Task  Force  reinforces  the
tatement  that  mitral  valve  repair  should  be  the  preferred
echnique  when  it  is  expected  to  be  durable.  As  a  con-
equence,  it  is  important  to  increase  surgical  expertise
nd  the  number  of  reference  centres  for  this  frequent  dis-
ase.
Here  again  the  indications  in  the  asymptomatic  patients
ith  primary  mitral  regurgitation  are  still  a matter  of
ebate,  but  the  Task  Force  widened  the  indications  and  pro-
osed  that  surgery  should  be  considered  in  asymptomatic
atients  with  preserved  left  ventricular  function,  high  like-
ihood  of  durable  repair,  low  surgical  risk,  ﬂail  leaﬂet  and
eft  ventricular  end-systolic  diameter  greater  than  40  mm.
urgery  may  also  be  considered  in  such  patients  in  cases  with
evere  dilatation  of  the  left  atrium  or  pulmonary  hyperten-
ion  on  exercise  echocardiography.
Following  results  from  the  EVEREST  trials  [9]  and  Euro-
ean  registries  [10], edge-to-edge  percutaneous  mitral
alve  repair  is  reported  to  be  relatively  safe  and  to  improve
ymptoms,  but  the  procedure  reduces  mitral  regurgitation
ess  effectively  than  mitral  valve  surgery.  Thus  the  Task
orce  stated  that  percutaneous  mitral  valve  repair  using  the
dge-to-edge  technique  may  be  considered  in  high-risk  or
noperable  patients  refractory  to  optimal  medical  manage-
ent  with  the  aim  of  improving  symptoms.  However,  longer
ollow-up  is  needed  as  well  as  data  from  randomized  clinical
rials.
Tricuspid  disease  should  not  be  forgotten,  and  surgery
hould  be  carried  out  early  enough  to  avoid  irreversible
ight  ventricular  dysfunction.  Surgery  should  be  considered
n  patients  with  mild  or  moderate  secondary  tricuspid  regur-
itation  with  dilated  annulus,  undergoing  left-sided  valve
urgery.
The  choice  of  the  type  of  valve  prosthesis  remains  a  dif-
cult  issue,  which  should  be  individualized  and  discussed  in
etail  with  the  patient  and  surgeon,  taking  into  account  mul-
iple  factors.  Age  is  one  of  the  parameters  for  the  decision,
nd  to  follow  the  widening  of  the  indications  for  bioprosthe-
is,  the  age  limit  for  implanting  a  bioprosthesis  was  lowered
o  60—65  years  for  patients  who  should  receive  an  aortic
lar  h
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prosthesis,  and  to  65—70  years  in  the  case  of  mitral  pros-
thesis.
Finally  with  regard  to  the  debated  issue  of  antithrombotic
therapy  after  valve  surgery,  the  need  for  a  3-month  period
of  postoperative  anticoagulant  therapy  has  been  challenged
in  patients  with  aortic  bioprostheses.  The  use  of  low-dose
aspirin  is  now  favoured  as  an  alternative  on  the  basis  of
data  from  registries.  On  the  other  hand,  oral  anticoagula-
tion  should  still  be  considered  for  the  ﬁrst  3  months  after
implantation  of  a  mitral  or  tricuspid  bioprosthesis  or  mitral
valve  repair.
The  overall  message  of  this  document  is  to  stress  the
importance  of  the  comprehensive  evaluation  of  the  car-
diac  and  extracardiac  condition  of  the  patient,  constantly
checking  consistency  between  the  results  of  diagnostic
investigation  and  clinical  ﬁndings  at  each  step  of  the
decision-making  process.  The  decision-making  process  and
the  management  of  the  patient  should  ideally  be  made
by  the  Heart  Team  with  particular  expertise  in  valve  dis-
ease.  Furthermore,  and  importantly,  owing  to  the  paucity  of
evidence-based  data  in  the  ﬁeld  of  valvular  heart  disease,
leading  to  most  recommendations  being  based  on  expert
consensus,  the  Task  Force  pleads  for  an  increase  in  the
research  efforts  in  this  ﬁeld.
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